Mesenchymal stem cells (MSCs) now are popular stem cells for clinical applications. To date, MSCs were accepted in various disease treatments with several FDA-approved treatments in some countries. One important requirement for the clinical usage of stem cells is the production of stem cells. Actually, the treatment efficacy of MSC transplantation depends on the quality of transplanted MSCs. This review aimed to present some guidelines for MSC production according to good manufacturing practice that helps to maintain the quality of stem cells from batch to batch as well as the clinical satisfaction.
Introduction
Stem cell transplantation is a novel treatment method for many diseases, especially degenerative diseases. There are reports of the clinical application of stem cells for more than 70 diseases. Mesenchymal stem cells (MSCs) have become popular for disease treatment in recent years via two approaches: personalized medicine (autologous transplantation) and as a stem cell drug (allogeneic transplantation) (Larsen and Lewis, 2011; Squillaro et al., 2015) .
According to clinicaltrials.gov (2015) , there are currently about 560 clinical trials using MSCs from several sources ( at C a n a d a 1 1
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North Asia 10 epidermal growth factor (EGF), basic fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) (Tarte et al., 2010) . Although these media are simple, inexpensive, and convenient for ex vivo MSC culture, they contain a xenogeneic source of GFs and proteins (from FCS) with a high risk of disease transmission. Potential risks are also related to allergies against xenoproteins and transmission of prions and viruses.
In the next generation of culture media for MSCs, However, it is sometimes detrimental for patients to undergo blood withdrawal. Therefore, allogeneic blood has been used as a replacement. Allogeneic samples must be subjected to serological and nucleic acid testing of blood-transmitted viruses, such as human immunodeficiency virus (HIV) and hepatitis C virus, with a supplemental step of virus inactivation before use as a supplement in culture medium.
There are two forms of blood-based products used in ex vivo culture: plasma platelet lysate (PL) and platelet rich plasma (PRP). Recent reports show that PRP is the most reliable and used product to grow MSCs from diverse sources, such as bone marrow, adipose tissue, umbilical cord, and dental pulp tissue. Only 2%-8% PRP stimulates MSC proliferation with a higher efficacy than FCS (Fekete et al., 2012) . In fact, PRP is a pool of many GFs, including EGF, acidic FGF, PDGF, transforming growth factor, keratocyte growth factor, hepatocyte growth factor, and insulin-like growth factor. These are human
GFs and efficiently stimulate MSCs compared with bovine GFs in FCS (Fekete et al., 2012 (Chen et al., 2014b) . In another study, aneuploidy has been detected by some studies when MSCs are cultured (Tarte et al., 2010) .
However, they also confirmed that these modifications did not cause tumorigenesis of MSCs (Chen et al., 2014a; Tarte et al., 2010; Wang et al., 2013) . MSCs also maintain stemness after long-term culture with a stable phenotype, self-renewal, and differentiation potential (Wang et al., 2013) . Although monolayer culture has a high risk of (Rojewski et al., 2013) . Although this system can provide optimal tools for delivering MSCs of clinical grade, which comply with GMP, the behavior or properties of MSCs can change in this platform (Guo et al., 2014) . In a recent study, a low oxygen concentration was used to maintain the growth and genetic stability of MSCs cultured in suspension culture (Bigot et al., 2015; Estrada et al., 2012; Hung et al., 2012; Oliveira et al., 2012) . In another report, three-dimensional culture increased the antiinflammatory properties of MSCs (Bartosh et al., 2010; Hong et al., 2015) .
Harvesting adherent cells
MSCs must be cultured as adherent cells in both monolayer and suspension culture. After expansion, to Dominici et al (2006) , there are two groups of markers used to confirm MSCs: positive markers (CD13, CD44, CD73, CD90, and CD105) and negative markers (CD14, CD34, CD45, and HLA-DR). Profile marker kits for these have been commercialized to confirm MSC phenotypes (Dominici et al., 2006) .
Conclusion
MSC production with GMP compliance (Fig.3) appears to be a compelling condition to use MSCs in clinical application. GMP will maintain the quality and safety of MSCs. Clinical grade MSCs are only produced by application of regulations as well as the requirements or elements of GMP. However, all procedures should originate from clinical demands. GMP is not a standard but a set of guidelines or rules for production procedures with the highest quality and safety.
